AVIR is currently developing the following drugs: Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir, Treatment A-Bemnifosbuvir/Ruzasvir Fdc Administered Fasting, Treatment B-Omeprazole 20 Mg Dose Administered Fasting, Treatment C-Bemnifosbuvir/Ruzasvir Fdc Administered Simultaneously With 20 Mg Dose Of Omeprazole Fasting, Treatment D-Bemnifosbuvir/Ruzasvir Fdc Administered 0.5 Hour Prior To 20 Mg Dose Of Omeprazole, Treatment E-Omeprazole 40 Mg Administered Fasting, Treatment F-Bemnifosbuvir/Ruzasvir Fdc Administered 2 Hours After 40 Mg Dose Omeprazole, Digoxin Vs Digoxin + Bem/Rzr Vs Digoxin + 2H Bem/Rzr, Rosuvastatin Vs Rosuvastatin + Bem/Rzr Vs Rosuvastatin + 2H Bem/Rzr. These drug candidates are in various stages of clinical development as the company works toward FDA approval.